Zurück zur Übersicht
| Leukemia. 2015 Feb 5. pii: leu201529. doi: 10.1038/leu.2015.29. pmc: PMC4430701 |
| Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. |
| Cross NC1, White HE2, Colomer D3, Ehrencrona H4, Foroni L5, Gottardi E6, Lange T7, Lion T8, Machova Polakova K9, Dulucq S10, Martinelli G11, Oppliger Leibundgut E12, Pallisgaard N13, Barbany G14, Sacha T15, Talmaci R16, Izzo B17, Saglio G18, Pane F19, Müller MC20, Hochhaus A21 |
 Author information
|
|
Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants. |
|
Publikations ID: 25652737 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
